Global Opioid-Induced Constipation Market Growth 2021-2026

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Opioid-Induced Constipation Consumption 2016-2026
2.1.2 Opioid-Induced Constipation Consumption CAGR by Region
2.2 Opioid-Induced Constipation Segment by Type
2.2.1 Methylnaltrexone Bromide
2.2.2 Lubiprostone
2.2.3 Naloxegol
2.2.4 Others
2.3 Opioid-Induced Constipation Sales by Type
2.3.1 Global Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
2.3.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2016-2021)
2.3.3 Global Opioid-Induced Constipation Sale Price by Type (2016-2021)
2.4 Opioid-Induced Constipation Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.5 Opioid-Induced Constipation Sales by Application
2.5.1 Global Opioid-Induced Constipation Sale Market Share by Application (2016-2021)
2.5.2 Global Opioid-Induced Constipation Revenue and Market Share by Application (2016-2021)
2.5.3 Global Opioid-Induced Constipation Sale Price by Application (2016-2021)

3 Global Opioid-Induced Constipation by Company
3.1 Global Opioid-Induced Constipation Sales Market Share by Company
3.1.1 Global Opioid-Induced Constipation Sales by Company (2019-2021)
3.1.2 Global Opioid-Induced Constipation Sales Market Share by Company (2019-2021)
3.2 Global Opioid-Induced Constipation Revenue Market Share by Company
3.2.1 Global Opioid-Induced Constipation Revenue by Company (2019-2021)
3.2.2 Global Opioid-Induced Constipation Revenue Market Share by Company (2019-2021)
3.3 Global Opioid-Induced Constipation Sale Price by Company
3.4 Global Manufacturers Opioid-Induced Constipation Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Opioid-Induced Constipation Product Location Distribution
3.4.2 Players Opioid-Induced Constipation Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Opioid-Induced Constipation by Region
4.1 Global Opioid-Induced Constipation by Region
4.1.1 Global Opioid-Induced Constipation Sales by Region
4.1.2 Global Opioid-Induced Constipation Revenue by Region
4.2 Americas Opioid-Induced Constipation Sales Growth
4.3 APAC Opioid-Induced Constipation Sales Growth
4.4 Europe Opioid-Induced Constipation Sales Growth
4.5 Middle East & Africa Opioid-Induced Constipation Sales Growth

5 Americas
5.1 Americas Opioid-Induced Constipation Sales by Country
5.1.1 Americas Opioid-Induced Constipation Sales by Country (2016-2021)
5.1.2 Americas Opioid-Induced Constipation Revenue by Country (2016-2021)
5.2 Americas Opioid-Induced Constipation Sales by Type
5.3 Americas Opioid-Induced Constipation Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Opioid-Induced Constipation Sales by Region
6.1.1 APAC Opioid-Induced Constipation Sales by Region (2016-2021)
6.1.2 APAC Opioid-Induced Constipation Revenue by Region (2016-2021)
6.2 APAC Opioid-Induced Constipation Sales by Type
6.3 APAC Opioid-Induced Constipation Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Opioid-Induced Constipation by Country
7.1.1 Europe Opioid-Induced Constipation Sales by Country (2016-2021)
7.1.2 Europe Opioid-Induced Constipation Revenue by Country (2016-2021)
7.2 Europe Opioid-Induced Constipation Sales by Type
7.3 Europe Opioid-Induced Constipation Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Opioid-Induced Constipation by Country
8.1.1 Middle East & Africa Opioid-Induced Constipation Sales by Country (2016-2021)
8.1.2 Middle East & Africa Opioid-Induced Constipation Revenue by Country (2016-2021)
8.2 Middle East & Africa Opioid-Induced Constipation Sales by Type
8.3 Middle East & Africa Opioid-Induced Constipation Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Opioid-Induced Constipation Distributors
10.3 Opioid-Induced Constipation Customer

11 Global Opioid-Induced Constipation Market Forecast
11.1 Global Opioid-Induced Constipation Forecast by Region
11.1.1 Global Opioid-Induced Constipation Forecast by Regions (2021-2026)
11.2.2 Global Opioid-Induced Constipation Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Countries
11.3 APAC Forecast by Region
11.4 Europe Forecast by Countries
11.5 Middle East & Africa Forecast by Countries
11.6 Global Opioid-Induced Constipation Forecast by Type
11.7 Global Opioid-Induced Constipation Forecast by Application

12 Key Players Analysis
12.1 Takeda Pharmaceuticals
12.1.1 Takeda Pharmaceuticals Takeda Pharmaceuticals Company Information
12.1.2 Takeda Pharmaceuticals Opioid-Induced Constipation Product Offered
12.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Takeda Pharmaceuticals Main Business Overview
12.1.5 Takeda Pharmaceuticals Latest Developments
12.2 Bayer
12.2.1 Bayer Company Information
12.2.2 Bayer Opioid-Induced Constipation Product Offered
12.2.3 Bayer Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Bayer Main Business Overview
12.2.5 Bayer Latest Developments
12.3 Sanofi
12.3.1 Sanofi Company Information
12.3.2 Sanofi Opioid-Induced Constipation Product Offered
12.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 Sanofi Main Business Overview
12.3.5 Sanofi Latest Developments
12.4 Mallinckrodt
12.4.1 Mallinckrodt Company Information
12.4.2 Mallinckrodt Opioid-Induced Constipation Product Offered
12.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 Mallinckrodt Main Business Overview
12.4.5 Mallinckrodt Latest Developments
12.5 Salix (Bausch Health)
12.5.1 Salix (Bausch Health) Company Information
12.5.2 Salix (Bausch Health) Opioid-Induced Constipation Product Offered
12.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Salix (Bausch Health) Main Business Overview
12.5.5 Salix (Bausch Health) Latest Developments
12.6 AstraZeneca
12.6.1 AstraZeneca Company Information
12.6.2 AstraZeneca Opioid-Induced Constipation Product Offered
12.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 AstraZeneca Main Business Overview
12.6.5 AstraZeneca Latest Developments
12.7 Progenics Pharmaceuticals
12.7.1 Progenics Pharmaceuticals Company Information
12.7.2 Progenics Pharmaceuticals Opioid-Induced Constipation Product Offered
12.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Progenics Pharmaceuticals Main Business Overview
12.7.5 Progenics Pharmaceuticals Latest Developments
12.8 Purdue Pharm
12.8.1 Purdue Pharm Company Information
12.8.2 Purdue Pharm Opioid-Induced Constipation Product Offered
12.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.8.4 Purdue Pharm Main Business Overview
12.8.5 Purdue Pharm Latest Developments
12.9 Nektar Therapeutics
12.9.1 Nektar Therapeutics Company Information
12.9.2 Nektar Therapeutics Opioid-Induced Constipation Product Offered
12.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.9.4 Nektar Therapeutics Main Business Overview
12.9.5 Nektar Therapeutics Latest Developments
12.10 Daiichi Sankyo
12.10.1 Daiichi Sankyo Company Information
12.10.2 Daiichi Sankyo Opioid-Induced Constipation Product Offered
12.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.10.4 Daiichi Sankyo Main Business Overview
12.10.5 Daiichi Sankyo Latest Developments
12.11 Prestige
12.11.1 Prestige Company Information
12.11.2 Prestige Opioid-Induced Constipation Product Offered
12.11.3 Prestige Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.11.4 Prestige Main Business Overview
12.11.5 Prestige Latest Developments
12.12 GSK
12.12.1 GSK Company Information
12.12.2 GSK Opioid-Induced Constipation Product Offered
12.12.3 GSK Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.12.4 GSK Main Business Overview
12.12.5 GSK Latest Developments
12.13 Shionogi
12.13.1 Shionogi Company Information
12.13.2 Shionogi Opioid-Induced Constipation Product Offered
12.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)
12.13.4 Shionogi Main Business Overview
12.13.5 Shionogi Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Opioid-Induced Constipation Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Methylnaltrexone Bromide
Table 3. Major Players of Lubiprostone
Table 4. Major Players of Naloxegol
Table 5. Major Players of Others
Table 6. Global Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 7. Global Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
Table 8. Global Opioid-Induced Constipation Revenue by Type (2016-2021) & ($ million)
Table 9. Global Opioid-Induced Constipation Revenue Market Share by Type (2016-2021)
Table 10. Global Opioid-Induced Constipation Sale Price by Type (2016-2021)
Table 11. Global Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 12. Global Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Table 13. Global Opioid-Induced Constipation Value by Application (2016-2021)
Table 14. Global Opioid-Induced Constipation Revenue Market Share by Application (2016-2021)
Table 15. Global Opioid-Induced Constipation Sale Price by Application (2016-2021)
Table 16. Global Opioid-Induced Constipation Sales by Company (2019-2021) & (K Units)
Table 17. Global Opioid-Induced Constipation Sales Market Share by Company (2019-2021)
Table 18. Global Opioid-Induced Constipation Revenue by Company (2019-2021) ($ Millions)
Table 19. Global Opioid-Induced Constipation Revenue Market Share by Company (2019-2021)
Table 20. Global Opioid-Induced Constipation Sale Price by Company (2019-2021)
Table 21. Key Manufacturers Opioid-Induced Constipation Producing Area Distribution and Sales Area
Table 22. Players Opioid-Induced Constipation Products Offered
Table 23. Opioid-Induced Constipation Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Opioid-Induced Constipation Sales by Region (2016-2021) (K Units)
Table 27. Global Opioid-Induced Constipation Sales Market Share by Region (2016-2021)
Table 28. Global Opioid-Induced Constipation Revenue by Region (2016-2021) & ($ Millions)
Table 29. Global Opioid-Induced Constipation Revenue Market Share by Region (2016-2021)
Table 30. Americas Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 31. Americas Opioid-Induced Constipation Sales Market Share by Country (2016-2021)
Table 32. Americas Opioid-Induced Constipation Revenue by Country (2016-2021) & ($ Millions)
Table 33. Americas Opioid-Induced Constipation Revenue Market Share by Country (2016-2021)
Table 34. Americas Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 35. Americas Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
Table 36. Americas Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 37. Americas Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Table 38. APAC Opioid-Induced Constipation Sales by Region (2016-2021) & (K Units)
Table 39. APAC Opioid-Induced Constipation Sales Market Share by Region (2016-2021)
Table 40. APAC Opioid-Induced Constipation Revenue by Region (2016-2021) & ($ Millions)
Table 41. APAC Opioid-Induced Constipation Revenue Market Share by Region (2016-2021)
Table 42. APAC Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 43. APAC Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
Table 44. APAC Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 45. APAC Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Table 46. Europe Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 47. Europe Opioid-Induced Constipation Sales Market Share by Country (2016-2021)
Table 48. Europe Opioid-Induced Constipation Revenue by Country (2016-2021) & ($ Millions)
Table 49. Europe Opioid-Induced Constipation Revenue Market Share by Country (2016-2021)
Table 50. Europe Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 51. Europe Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
Table 52. Europe Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 53. Europe Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Table 54. Middle East & Africa Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 55. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Country (2016-2021)
Table 56. Middle East & Africa Opioid-Induced Constipation Revenue by Country (2016-2021) & ($ Millions)
Table 57. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Country (2016-2021)
Table 58. Middle East & Africa Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 59. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
Table 60. Middle East & Africa Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 61. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Table 62. Global Opioid-Induced Constipation Sales Forecast by Type (2021-2026) & (K Units)
Table 63. Global Opioid-Induced Constipation Sales Market Share Forecast by Type (2021-2026)
Table 64. Global Opioid-Induced Constipation Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 65. Global Opioid-Induced Constipation Revenue Market Share Forecast by Type (2021-2026)
Table 66. Global Opioid-Induced Constipation Sales Forecast by Application (2021-2026) & (K Units)
Table 67. Global Opioid-Induced Constipation Sales Market Share Forecast by Application (2021-2026)
Table 68. Global Opioid-Induced Constipation Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 69. Global Opioid-Induced Constipation Revenue Market Share Forecast by Application (2021-2026)
Table 70. Takeda Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 71. Takeda Pharmaceuticals Opioid-Induced Constipation Product Offered
Table 72. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 73. Takeda Pharmaceuticals Main Business
Table 74. Takeda Pharmaceuticals Latest Developments
Table 75. Bayer Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 76. Bayer Opioid-Induced Constipation Product Offered
Table 77. Bayer Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 78. Bayer Main Business
Table 79. Bayer Latest Developments
Table 80. Sanofi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 81. Sanofi Opioid-Induced Constipation Product Offered
Table 82. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 83. Sanofi Main Business
Table 84. Sanofi Latest Developments
Table 85. Mallinckrodt Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 86. Mallinckrodt Opioid-Induced Constipation Product Offered
Table 87. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 88. Mallinckrodt Main Business
Table 89. Mallinckrodt Latest Developments
Table 90. Salix (Bausch Health) Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 91. Salix (Bausch Health) Opioid-Induced Constipation Product Offered
Table 92. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 93. Salix (Bausch Health) Main Business
Table 94. Salix (Bausch Health) Latest Developments
Table 95. AstraZeneca Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 96. AstraZeneca Opioid-Induced Constipation Product Offered
Table 97. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 98. AstraZeneca Main Business
Table 99. AstraZeneca Latest Developments
Table 100. Progenics Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 101. Progenics Pharmaceuticals Opioid-Induced Constipation Product Offered
Table 102. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 103. Progenics Pharmaceuticals Main Business
Table 104. Progenics Pharmaceuticals Latest Developments
Table 105. Purdue Pharm Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 106. Purdue Pharm Opioid-Induced Constipation Product Offered
Table 107. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 108. Purdue Pharm Main Business
Table 109. Purdue Pharm Latest Developments
Table 110. Nektar Therapeutics Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 111. Nektar Therapeutics Opioid-Induced Constipation Product Offered
Table 112. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 113. Nektar Therapeutics Main Business
Table 114. Nektar Therapeutics Latest Developments
Table 115. Daiichi Sankyo Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 116. Daiichi Sankyo Opioid-Induced Constipation Product Offered
Table 117. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 118. Daiichi Sankyo Main Business
Table 119. Daiichi Sankyo Latest Developments
Table 120. Prestige Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 121. Prestige Opioid-Induced Constipation Product Offered
Table 122. Prestige Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 123. Prestige Main Business
Table 124. Prestige Latest Developments
Table 125. GSK Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 126. GSK Opioid-Induced Constipation Product Offered
Table 127. GSK Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 128. GSK Main Business
Table 129. GSK Latest Developments
Table 130. Shionogi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 131. Shionogi Opioid-Induced Constipation Product Offered
Table 132. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 133. Shionogi Main Business
Table 134. Shionogi Latest Developments
List of Figures
Figure 1. Picture of Opioid-Induced Constipation
Figure 2. Opioid-Induced Constipation Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Opioid-Induced Constipation Sales Growth Rate 2016-2026 (K Units)
Figure 7. Global Opioid-Induced Constipation Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Opioid-Induced Constipation Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Methylnaltrexone Bromide
Figure 10. Product Picture of Lubiprostone
Figure 11. Product Picture of Naloxegol
Figure 12. Product Picture of Others
Figure 13. Global Opioid-Induced Constipation Sales Market Share by Type in 2020
Figure 14. Global Opioid-Induced Constipation Revenue Market Share by Type (2016-2021)
Figure 15. Opioid-Induced Constipation Consumed in Hospital
Figure 16. Global Opioid-Induced Constipation Market: Hospital (2016-2021) & (K Units)
Figure 17. Opioid-Induced Constipation Consumed in Pharmacy
Figure 18. Global Opioid-Induced Constipation Market: Pharmacy (2016-2021) & (K Units)
Figure 19. Global Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Figure 20. Global Opioid-Induced Constipation Revenue Market Share by Application in 2020
Figure 21. Global Opioid-Induced Constipation Revenue Market by Company in 2020 ($ Million)
Figure 22. Global Opioid-Induced Constipation Revenue Market Share by Company in 2020
Figure 23. Global Opioid-Induced Constipation Sales Market Share by Regions (2016-2021)
Figure 24. Global Opioid-Induced Constipation Revenue Market Share by Region in 2020
Figure 25. Americas Opioid-Induced Constipation Sales 2016-2021 (K Units)
Figure 26. Americas Opioid-Induced Constipation Revenue 2016-2021 ($ Millions)
Figure 27. APAC Opioid-Induced Constipation Sales 2016-2021 (K Units)
Figure 28. APAC Opioid-Induced Constipation Revenue 2016-2021 ($ Millions)
Figure 29. Europe Opioid-Induced Constipation Sales 2016-2021 (K Units)
Figure 30. Europe Opioid-Induced Constipation Revenue 2016-2021 ($ Millions)
Figure 31. Middle East & Africa Opioid-Induced Constipation Sales 2016-2021 (K Units)
Figure 32. Middle East & Africa Opioid-Induced Constipation Revenue 2016-2021 ($ Millions)
Figure 33. Americas Opioid-Induced Constipation Sales Market Share by Country in 2020
Figure 34. Americas Opioid-Induced Constipation Revenue Market Share by Country in 2020
Figure 35. Americas Opioid-Induced Constipation Sales Market Share by Type in 2020
Figure 36. Americas Opioid-Induced Constipation Sales Market Share by Application in 2020
Figure 37. United States Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 38. Canada Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 39. Mexico Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 40. Brazil Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 41. APAC Opioid-Induced Constipation Sales Market Share by Region in 2020
Figure 42. APAC Opioid-Induced Constipation Revenue Market Share by Regions in 2020
Figure 43. APAC Opioid-Induced Constipation Sales Market Share by Type in 2020
Figure 44. APAC Opioid-Induced Constipation Sales Market Share by Application in 2020
Figure 45. China Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 46. Japan Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 47. Korea Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 48. Southeast Asia Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 49. India Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 50. Australia Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 51. Europe Opioid-Induced Constipation Sales Market Share by Country in 2020
Figure 52. Europe Opioid-Induced Constipation Revenue Market Share by Country in 2020
Figure 53. Europe Opioid-Induced Constipation Sales Market Share by Type in 2020
Figure 54. Europe Opioid-Induced Constipation Sales Market Share by Application in 2020
Figure 55. Germany Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 56. France Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 57. UK Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 58. Italy Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 59. Russia Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 60. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Country in 2020
Figure 61. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Country in 2020
Figure 62. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Type in 2020
Figure 63. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Application in 2020
Figure 64. Egypt Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 65. South Africa Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 66. Israel Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 67. Turkey Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 68. GCC Country Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)
Figure 69. Channels of Distribution
Figure 70. Distributors Profiles

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.